Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer

E-ISSN： 1873-5592|15|6|622-634

ISSN： 1389-4501

Source： Current Drug Targets, Vol.15, Iss.6, 2014-06, pp. : 622-634

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Curcumin: A Natural Pan-HDAC Inhibitor in Cancer

Current Pharmaceutical Design, Vol. 24, Iss. 2, 2018-04 ,pp. : 123-129

Bentham Science Publishers

Access to resources Recommend Favorite

Panobinostat for the treatment of multiple myeloma

By Neri Paola Bahlis Nizar J Lonial Sagar

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 5, 2012-05 ,pp. : 733-747

Informa Healthcare

Access to resources Recommend Favorite

Comprehensive Analysis for Histone Acetylation of Human Colon Cancer Cells Treated with a novel HDAC Inhibitor

Current Pharmaceutical Design, Vol. 20, Iss. 11, 2014-04 ,pp. : 1866-1873

Bentham Science Publishers

Access to resources Recommend Favorite

The Changing Face of HDAC Inhibitor Depsipeptide

Current Cancer Drug Targets, Vol. 9, Iss. 1, 2009-02 ,pp. : 91-100

Bentham Science Publishers

Access to resources Recommend Favorite

Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 210-216

John Wiley & Sons Inc

Access to resources Recommend Favorite